Dr. Eric Klein, Distinguished Scientist at GRAIL, provides a research update from GRAIL’s 2024 findings on multi-cancer early detection (MCED) testing, presented at ASCO, ESMO, AACR and more. He explores insights from the first real-world evaluation of repeat multi-cancer early detection testing, data on how multi-cancer early detection (MCED) testing is helping cancer survivors by detecting recurrence and new cancers, and findings on using MCED to detect high grade, clinically significant prostate cancer over indolent cases. Plus, the economic and emotional impacts of cancer screening, and three insightful case studies. 

Watch the full episode on YouTube: https://youtu.be/QU6s3P1B5Bo 

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN 

Transcripts: https://grail.com/podcast/ 

Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/ 

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests. 

Rx only. See Important Safety Information: https://www.galleri.com/safety-information 

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis. 

At their doctor’s recommendation, Rich and Staci each took a multi-cancer early detection test during a routine checkup. Despite having no symptoms, Rich received a Cancer Signal Detected result, while Staci, who had a strong family history of cancer, did not. Listen to their story and learn about the impact of early cancer detection.

Watch the full episode on YouTube: https://youtu.be/NKY3lX9PGYs  

View Rich and Staci’s story: https://youtu.be/z7M_ebq4Tj4?si=-C9cGsmx7MFzcKzc 

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN 

Transcripts: https://grail.com/podcast/ 

Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/ 

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests. 

See Important Safety Information: http://bit.ly/33m8pFa 

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.

Seven in 10 Americans are behind on at least one routine cancer screening. Jody Hoyos, CEO of the Prevent Cancer Foundation, joins Susanna to discuss the critical role of early cancer detection. She addresses the most common misconceptions about cancer screening  and explains the importance of proactive screening, even when no symptoms are present.

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN 

Transcripts: https://grail.com/podcast/ 

Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

Introducing our new host, Susanna Quinn! Susanna is a cancer survivor, entrepreneur, writer and philanthropist. Diagnosed with stage three ovarian cancer in 2019, Susanna underwent aggressive treatment and achieved cancer-free status by September of the same year. In this episode, Kim Thiboldeaux, the Cancer SIGNAL’s inaugural host, interviews Susanna about her cancer story and passes the torch. 

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN 

Transcripts: https://grail.com/podcast/ 

Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

Dr. Scout, Executive Director of the National LGBT Cancer Network, discusses how the LGBTQ+ community faces unique challenges in cancer screening. Dr. Scout highlights the increased cancer risks due to social factors, like discrimination and medical mistrust, and emphasizes the importance of inclusive healthcare provider training. The National LGBT Cancer Network works to educate both the community and providers, runs support groups for LGBTQ+ cancer survivors, and is developing a more comprehensive list of welcoming providers. 

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN 

Transcripts: https://grail.com/podcast/ 

Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

Jon Rendina and Dwight Venson of Whitman-Walker, a healthcare center historically focused on the LGBTQ+ community, join us to delve into how LGBTQ+ people and people of color face disparities in cancer incidence. Whitman-Walker, Cancer Support Community, and GRAIL are collaborating on INCLUDE, a study to evaluate multi-cancer early detection (MCED) testing’s impact within federally qualified health centers. The goal: make this kind of cancer screening available to more people in the future. Jon and Dwight discuss barriers to access, how LGTBQ+ and minority experiences of cancer care can be different, and how MCED testing may play a role in helping underserved groups.

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN 

Transcripts: https://grail.com/podcast/ 

Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

Diverse clinical trials provide more meaningful data to researchers, but too many trials are based around monolithic audience groups. In early disease detection, particularly in conditions like cancer, diversity in clinical trials is especially important. Our guests, Eucharia Borden of the cancer nonprofit Family Reach and Dr. Gary Puckrein of the National Minority Quality Forum, discuss why diversity in clinical trials is critical and how to foster inclusivity in clinical research, getting us closer to healthcare equity. 

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN 

Transcripts: https://grail.com/podcast/ 

Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

After supporting her husband through his shocking cancer experience, Cindy decided to take a multi-cancer early detection test as recommended by her doctor. She was once again shocked when she received a “cancer signal detected” result, leading to a cancer diagnosis. Join us to hear about Cindy’s experience with early detection, treatment, and eventual remission, and what she learned along the way.

We want your feedback! Please take our podcast survey: https://bit.ly/42R4wGi 

Transcripts: https://grail.com/podcast/ 

Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

Join host Kim Thiboldeaux and Krissa Smith, VP of Mission Partnerships at Susan G. Komen, as they continue unraveling how the BRCA gene and other DNA mutations impact hereditary cancer risk. In this episode, Krissa shares personal stories about her family's experiences with genetic testing and how they’ve chosen to respond. Krissa also discusses cancer screening best practices and how multi-cancer early detection testing can play a role.

Please take our survey to help us shape future episodes: https://bit.ly/3sQkbrN   Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

Krissa Smith, Vice President of Mission Partnerships at Susan G. Komen, joins us to discuss the complexities of the BRCA gene and its impact on hereditary cancer risk. Krissa shares her family's experiences with genetic mutations, including the p53 gene, and explains the importance of genetic testing and how it can work in partnership with evolving cancer screening technology. Stay tuned for part 2 to learn more about genetics, cancer risk, and the importance of early detection.

Please take our survey to help us shape future episodes: https://bit.ly/3sQkbrN   Transcripts: https://grail.com/podcast/ Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/